

# Investor Relations Brief

12

2024

December



# Business Division Progress Report

## Molecular Diagnostics and Bio Division

From November 11–14, the Molecular Diagnostics and Bio Division showcased its innovative products and technologies at MEDICA 2024, the world's largest B2B medical device exhibition in Germany. Highlights included the HIV-1 VL Kit, the first in Asia to receive WHO PQ certification, the ExiStation™ System, and the full line of IRON-qPCR™ compatible assays, all of which garnered significant attention. The team also established plans to pursue public tenders for the HIV Kit through local business meetings and secured several new distribution partners.

Additionally, from November 12–16, the division participated in the 2024 Union World Conference on Lung Health in Indonesia, presenting the RFIA Kit, a multidrug-resistant tuberculosis diagnostic solution based on IRON-qPCR™, along with the recently WHO PQ-certified HIV-1 Kit. Networking activities included engagements with tuberculosis program leaders from key countries such as India, the Philippines, Nigeria, and Uganda. Close collaboration with influential stakeholders in these regions further solidified the division's foundation for expansion into global markets.

## CosmeRNA

On November 7, CosmeRNA was featured in the prestigious European Medical Journal (EMJ), where it was highlighted as a promising solution to address the limitations of existing hair loss treatments.

November 11 marked the celebration of CosmeRNA Hair Day, symbolizing hair transformation, and from November 15–17, CosmeRNA was officially launched in the UAE during MEDIAM 2024. Through its local distributor, Atlas Medical LLC, CosmeRNA will be swiftly supplied to hospitals, clinics, and hair loss treatment centers across the region.

In mid-December, CosmeRNA's 2mℓ product is set to launch on Amazon USA, expanding its availability through diverse global channels. With targeted marketing programs and campaigns aligned with the Christmas and year-end shopping season, CosmeRNA aims to establish itself as a leading global cosmetic solution for hair loss.

## siRNAgen

siRNAgen Therapeutics is collaborating with Seoul National University Hospital in South Korea to analyze data and finalize discussions for publishing the clinical trial results of SRN-001 in a more prestigious academic journal. This effort aims to clearly demonstrate the clinical value of SRN-001 and secure internationally recognized, objective evidence for the trial outcomes.

Additionally, preparations are underway for Phase 1b clinical trials, including the search for domestic and international GMP-certified CDMO partners to produce clinical trial-ready final products. Concurrently, the company is conducting a CRO selection process to facilitate the trials and is working with multiple experts and organizations to develop concrete implementation plans.

## CosmeRNA Officially Launched in the UAE at MEDIAM

From November 15–17, CosmeRNA, BIONEER’s hair loss cosmetic, was officially launched at MEIDAM 2024, a prestigious beauty exhibition held in the UAE.


Prior to the launch, user feedback collection and initial market testing conducted at specialized clinics in the UAE yielded highly positive responses. These results played a crucial role in demonstrating CosmeRNA’s effectiveness and compatibility with the local market. Building on this success, BIONEER anticipates continued growth in the Middle Eastern market.



## MEDICA: Accelerating Entry into the Global HIV Market

From November 11–14, BIONEER participated in MEDICA 2024, the world's largest B2B medical device exhibition, where it garnered attention by showcasing the HIV-1 VL Kit, the first in Asia to receive WHO PQ certification, along with the ExiStation™ system and the full range of IRON-qPCR™ compatible assays.

During the event, BIONEER advanced its plans to pursue public tenders for its HIV Kit through local business meetings and secured numerous new distribution partners, marking significant progress toward global market expansion.



## Union World Conference on Lung Health

From November 12–16, BIONEER participated in the Union World Conference on Lung Health held in Indonesia, where it introduced its multidrug-resistant tuberculosis diagnostic solution, the IRON-qPCR™ RFIA Kit, along with the WHO PQ-certified HIV-1 Kit.

During the conference, BIONEER engaged in networking with tuberculosis program leaders from key countries, including India, the Philippines, Nigeria, and Uganda, establishing collaborative frameworks to support its expansion into global markets.



## Technology Exchange Activities for Advancing the Industry

### International R&D Industry Convention




Held in Daejeon from November 28–29, the International Research Industry Convention 2024 centered on the theme of "Research and Development Innovation and Strengthening Global Cooperation for a Sustainable Future." In the opening address, Han-Oh Park, Chairman of the Korea Research Industry Association and Chairman of BIONEER, highlighted the pivotal role of the research industry in driving transformative change in an era of technological innovation. He also emphasized the immense potential of domestic research industry companies, expressing optimism that their groundbreaking achievements would play a crucial role in propelling South Korea into a global technology powerhouse.

At the event, Eun-Young Lee, Director of Research Outcomes Innovation at the Ministry of Science and ICT, emphasized the government's commitment to fostering the research industry to create an innovative and ambitious R&D ecosystem through collaboration between researchers and businesses.

Approximately 80 companies operated exhibition booths at the convention, where BIONEER showcased six of its research equipment products, actively promoting them to attendees. The event attracted numerous researchers and corporate R&D professionals from nearby research complexes, who expressed significant interest in BIONEER's products.

BIONEER also participated in the New Technology Seminar, where it presented its real-time gene amplification system, ExiCycler V5™, further enhancing its visibility and engagement with the research community.



## 2024 Asia Tuberculosis Elimination Forum



On November 6–7, BIONEER took part in the 7th Asia Tuberculosis Elimination Forum (Seeking Ways to Eliminate TB in Asia), hosted by the Korean National Tuberculosis Association and held at Seoul National University. Representing various companies, BIONEER presented its tuberculosis diagnostic system and outlined its research and development strategies aimed at eradicating tuberculosis.

